Won Hye Sung, Chun Sang Hoon, Kim Bum-Soo, Chung So Ryoung, Yoo Ie Ryung, Jung Chan-Kwon, Kim Yeon-Sil, Sun Dong-Il, Kim Min Sik, Kang Jin-Hyoung
Head and Neck Cancer Interdisciplinary Team, Departments of.
Rare Tumors. 2009 Dec 28;1(2):e36. doi: 10.4081/rt.2009.e36.
The standard treatment in the early stage of maxillary sinus cancer is surgical resection followed by postoperative radiation therapy. However, for locally advanced maxillary sinus cancer, a multimodality treatment approach is strongly recommended to improve the survival rate and quality of life of the patient. We determined the treatment outcomes of induction chemotherapy, concurrent chemoradiation therapy, and surgical resection for locally advanced maxillary sinus cancer. Forty-four patients with locally advanced maxillary sinus cancer, who had been treated between January 1990 and April 2008 at Kangnam St. Mary's Hospital, were retrospectively analyzed. The objective response rates were 70%, 53%, and 57% in the intra-arterial induction chemotherapy, intravenous induction chemotherapy, and concurrent chemoradiation therapy groups, respectively. The orbital preservation rates were 83%, 100%, and 75% in the intra-arterial induction chemotherapy, intravenous induction chemotherapy, and surgical resection groups, respectively. In seven of nine patients in whom the orbit could be preserved after induction chemotherapy, the primary tumors were removed completely. However, although the orbits were preserved in three patients who underwent surgical resection as a primary treatment, all three cases were confirmed to be incomplete resections. We found that active induction chemotherapy for locally advanced cancer of the maxillary sinus increased the possibility of complete resection with orbital preservation as well as tumor down-staging.
上颌窦癌早期的标准治疗方法是手术切除，术后进行放射治疗。然而，对于局部晚期上颌窦癌，强烈推荐采用多模式治疗方法，以提高患者的生存率和生活质量。我们确定了局部晚期上颌窦癌诱导化疗、同步放化疗和手术切除的治疗效果。对1990年1月至2008年4月在江南圣母医院接受治疗的44例局部晚期上颌窦癌患者进行了回顾性分析。动脉内诱导化疗、静脉内诱导化疗和同步放化疗组的客观缓解率分别为70%、53%和57%。动脉内诱导化疗、静脉内诱导化疗和手术切除组的眼眶保留率分别为83%、100%和75%。在诱导化疗后能够保留眼眶的9例患者中，有7例患者的原发肿瘤被完全切除。然而，尽管有3例患者作为初始治疗接受了手术切除且眼眶得以保留，但所有3例均被证实为不完全切除。我们发现，对上颌窦局部晚期癌症进行积极的诱导化疗增加了眼眶保留的完全切除以及肿瘤降期的可能性。
